Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: UK Approves Novavax Vaccine, EMA Updates On Progress With Other Candidates

Executive Summary

With the approval of Nuvaxovid, the UK and the EU now each have five COVID-19 vaccines at their disposal. Meanwhile, the European Medicines Agency has given an estimated timeline for the approval of candidate vaccines from Valneva and Sanofi Pasteur, and is looking at which therapeutics could be effective against the Omicron variant. Russia says its Sputnik V vaccine has now been granted full regulatory approval there.

You may also be interested in...



Sputnik COVID-19 Vaccine Caught Up In Sanctions On Russia Over Ukraine Invasion

As Russia intensifies its invasion of Ukraine with missile attacks and a convoy of armored vehicles, the funder and promoter of the country’s COVID-19 vaccine, Sputnik V, has found itself the subject of punitive international sanctions alongside Russia’s Central Bank.

Ex-US FDA Official Petitions Agency To Stop Reviewing Applications From Russian Companies Amid War In Ukraine

The request could drag the agency back into a political arena it has been trying to avoid.

EU Approves Paxlovid For COVID-19

The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel